Compare iShares MSCI Taiwan ETF (EWT) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Taiwan ETF vs Pfizer Inc — how do they compare? iShares MSCI Taiwan ETF trades at $114.31 (market cap $12.74B), while Pfizer Inc trades at $28.28 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 12.4× iShares MSCI Taiwan ETF's market cap, and Pfizer Inc pays a 6.18% dividend while iShares MSCI Taiwan ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Taiwan ETF for 52 Days and Pfizer Inc for 158 Days on average.
| EWT | PFE | |
|---|---|---|
Market Cap | $12.74B | $158.56B |
Volume | 8,470,920 | 44,138,282 |
Sector | Broad Market / Factor | Health |
52-Week High | $118.00 | $29.02 |
52-Week Low | $60.03 | $23.67 |
Typical Hold Time | 52 Days | 158 Days |
Enterprise Value | — | $210.06B |
Dividend Yield | — | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWT (iShares MSCI Taiwan ETF) trades at $113.34, down 2.49% on the day, with a bullish technical signal from moving averages despite neutral oscillators. The ETF remains heavily concentrated in Taiwan's semiconductor sector, particularly TSMC, benefiting from strong AI-driven demand. Recent news highlights Taiwan's $20 billion investment in US AI infrastructure and continued institutional interest, though geopolitical tensions with China present ongoing risks.
The outlook for EWT is positive due to Taiwan's critical role in AI semiconductor supply chains and reasonable tech valuations. Key opportunities include sustained AI demand and corporate investments, while risks center on China-Taiwan geopolitical friction and semiconductor cycle volatility. Wall Street maintains a bullish stance given growth-adjusted valuation metrics.
Pfizer (PFE) trades at $27.82, down 0.64% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company reported revenue of $62.58B in 2025 with a net income margin of 6.8%, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline, positioning for a catalyst-rich 2026.
The stock presents a value opportunity with a forward P/E of 36.61 and consensus price target of $29.17, but faces risks from patent cliffs and volatile cash flows. Analyst sentiment is mixed with 40% buy ratings, while institutional outlook remains cautious amid earnings pressure and competitive threats in the pharma sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Taiwan ETF
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
